Biocon Biologics announced on 17 October 2022 that it has entered into a strategic out-licensing agreement with Japanese pharmaceuticals company Yoshindo for commercializing two of its pipeline biosimilar assets in Japan. Following this, on 2 November 2022, Syna Therapeutics signed an exclusive license agreement with Intas to commercialize a haematology biosimilar.
Biocon-Yoshindo agreement
The Biocon-Yoshindo deal involves two biosimilar assets, bUstekinumab and bDenosumab. bUstekinumab, is a biosimilar referencing Janssen Pharmaceutical’s Stelara (ustekinumab), a monoclonal antibody used to treat several autoimmune conditions, including psoriasis, Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis [1]. Whereas bDenosumab, is a biosimilar referencing Amgen’s Prolia (denosumab), a monoclonal antibody for the treatment of osteoporosis [2].
Under the terms of the agreement, Yoshindo now has exclusive commercialization rights in Japan for bUstekinumab and bDenosumab that have been developed and manufactured by Biocon Biologics. The addressable market opportunity is estimated to be ~US$700 million. Biocon Biologics will receive an upfront license fee together with additional payments on the achievement of certain development milestones over the coming few years. However, the financial specifics have not been revealed.
Syna-Intas agreement
Syna Therapeutics is a joint venture of Reig Jofre and Leanbio, which has now signed a global licensing deal with Intas to commercialize its biosimilar drug LB-0702, developed to treat pathologies in the field of haematology. The originator/reference product has not been named.
Under the terms of the agreement, Syna will develop, manufacture and supply LB-0702 to Intas and its affiliates. Intas now has exclusive license rights to commercialize LB-0702 worldwide. The deal is key for Syna who can now take advantage of Inta’s subsidiary and biosimilars kingpin, Accord Healthcare’s sales and distribution networks in 85 countries.
Clinical trials for LB-0702 are due to start in 2023.
Related articles
New partnerships: Prestige-Intas and Samsung Bioepis-Samil
Ustekinumab biosimilars: new international biopharma agreements
Clinical trials begin for ustekinumab biosimilars
Theramex to market Prolia biosimilar in Europe and Australia
First subjects dosed in Australian phase I study of denosumab biosimilar
|
LATIN AMERICAN FORUM
The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. View the latest headline article: Hechos clave en la regulación de la aprobación de biosimilares en Brasil Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.
FORO LATINOAMERICANO
Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español. Ver el último artículo de cabecera: Hechos clave en la regulación de la aprobación de biosimilares en Brasil !Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.
|
References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of ustekinumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Nov 25]. Available from: www.gabionline.net/biosimilars/general/biosimilars-of-ustekinumab
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of denosumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Nov 25]. Available from: www.gabionline.net/biosimilars/general/Biosimilars-of-denosumab
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.
0
Post your comment